PriceTargets.com logo

Arcellx - ACLX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.60
  • Forecasted Upside: 48.65%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$29.33 As of 03/24/2023 01:00 AM ET
▲ +1.04 (3.68%)

This chart shows the closing price for ACLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcellx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACLX

Analyst Price Target is $43.60
▲ +48.65% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Arcellx in the last 3 months. The average price target is $43.60, with a high forecast of $104.00 and a low forecast of $32.00. The average price target represents a 48.65% upside from the last price of $29.33.

This chart shows the closing price for ACLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Arcellx.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/13/2023Stifel NicolausInitiated CoverageBuy$43.00Low
2/13/2023HC WainwrightInitiated CoverageBuy$42.00Low
12/13/2022Bank of AmericaReiterated RatingBuy$29.00 ➝ $37.00Low
12/12/2022Canaccord Genuity GroupBoost Target$32.00 ➝ $34.00Low
12/12/2022Needham & Company LLCBoost TargetBuy$31.00 ➝ $35.00Low
12/12/2022BarclaysBoost TargetOverweight$25.00 ➝ $38.00Low
12/9/2022Piper SandlerBoost Target$96.00 ➝ $104.00Low
11/24/2022SVB LeerinkLower Target$35.00Low
10/31/2022GuggenheimInitiated CoverageBuy$36.00Low
10/27/2022Needham & Company LLCInitiated CoverageBuy$31.00Low
7/20/2022Canaccord Genuity GroupInitiated CoverageBuy$32.00Low
7/20/2022Canaccord Genuity GroupInitiated CoverageBuy$32.00Low
6/23/2022SVB LeerinkLower TargetOutperform$47.00 ➝ $38.00Low
3/29/2022SVB LeerinkLower TargetOutperform$47.00 ➝ $44.00High
3/2/2022BarclaysInitiated CoverageOverweightMedium
3/1/2022William BlairReiterated RatingOutperformHigh
3/1/2022SVB LeerinkInitiated CoverageOutperform$47.00High
3/1/2022Bank of AmericaInitiated CoverageBuy$24.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.81 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Arcellx logo
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: $29.33
Low: $27.90
High: $29.46

50 Day Range

MA: $30.09
Low: $26.92
High: $33.94

52 Week Range

Now: $29.33
Low: $6.03
High: $35.26

Volume

245,423 shs

Average Volume

392,435 shs

Market Capitalization

$1.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcellx?

The following equities research analysts have issued stock ratings on Arcellx in the last year: Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Guggenheim, HC Wainwright, Needham & Company LLC, Piper Sandler, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for ACLX.

What is the current price target for Arcellx?

10 Wall Street analysts have set twelve-month price targets for Arcellx in the last year. Their average twelve-month price target is $43.60, suggesting a possible upside of 48.7%. Piper Sandler has the highest price target set, predicting ACLX will reach $104.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $32.00 for Arcellx in the next year.
View the latest price targets for ACLX.

What is the current consensus analyst rating for Arcellx?

Arcellx currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACLX will outperform the market and that investors should add to their positions of Arcellx.
View the latest ratings for ACLX.

What other companies compete with Arcellx?

Other companies that are similar to Arcellx include Iovance Biotherapeutics, Recursion Pharmaceuticals, Adaptive Biotechnologies, Replimune Group and Vericel. Learn More about companies similar to Arcellx.

How do I contact Arcellx's investor relations team?

The company's listed phone number is 240-327-0603 and its investor relations email address is [email protected] The official website for Arcellx is arcellx.com. Learn More about contacing Arcellx investor relations.